RIGL
NASDAQ
US
Rigel Pharmaceuticals, Inc. - Common Stock
$27.53
▲ +$0.03
(+0.11%)
Vol 186K
12
Quality Score
ok
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$777.4M
P/E
6.9
ROE
204.7%
Margin
40.2%
D/E
50.79
Beta
1.12
52W
$15–$52
Wall Street Consensus
12 analysts · Apr 20264
Strong Buy
4
Buy
4
Hold
0
Sell
0
Strong Sell
66.7%
Buy Rating
Price Chart
Similar Stocks
KYTX
Kyverna Therapeutics Inc
$537.0M
EIKN
Eikon Therapeutics Inc
CBIO
Crescent Biopharma Inc
$164.8M
ZURA
Zura Bio Ltd
$340.7M
UPB
Upstream Bio Inc
$1.5B
LRMR
Larimar Therapeutics Inc
$326.1M
TRDA
Entrada Therapeutics Inc
$392.9M
VSTM
Verastem Inc
$581.5M
LYEL
Lyell Immunopharma Inc
$653.9M
FDMT
4D Molecular Therapeutics Inc
$428.5M
Earnings
Beat rate: 75.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $1.27 | $1.15 | $-0.12 |
| Sep 2025 | $0.87 | $1.46 | +$0.59 |
| Jun 2025 | $2.63 | $3.28 | +$0.65 |
| Mar 2025 | $0.09 | $0.63 | +$0.54 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 246.9% | 246.9% | 246.9% | 246.9% | 204.7% | 204.7% |
| P/E (TTM) | 3.42 | 7.20 | 5.18 | 5.79 | 7.32 | 6.86 |
| Net Margin | 58.6% | 36.5% | 36.5% | 36.5% | 40.2% | 40.2% |
| Gross Margin | 95.6% | 91.5% | 91.5% | 91.5% | 93.1% | 93.1% |
| D/E Ratio | 73.00 | 73.00 | 73.00 | 73.00 | 50.79 | 50.79 |
| Current Ratio | 2.02 | 2.02 | 2.02 | 2.02 | 2.28 | 2.28 |
Key Ratios
ROA (TTM)
57.4%
P/S (TTM)
2.76
P/B
90.1
EPS (TTM)
$6.17
CF/Share
$-0.14
Rev Growth 3Y
+6.3%
52W High
$52.24
52W Low
$14.63
$14.63
52-Week Range
$52.24
How does RIGL compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
RIGL valuation vs Biotechnology peers
P/E ratio
6.9
▼
63%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
2.8
▼
79%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
90.1
▲
3563%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
RIGL profitability vs Biotechnology peers
ROE
204.7%
▲
404%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
40.2%
▲
114%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
93.1%
▲
18%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
57.4%
▲
223%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
RIGL financial health vs Biotechnology peers
D/E ratio
50.8
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
2.3
▼
49%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
1.1
▲
15%
above
peers
(1.0)
vs Peers
vs Industry
Less volatile
RIGL fundamentals radar
RIGL
Peer median
Industry
RIGL profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
RIGL vs peers: key metrics
Latest News
No related news yet